These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28434274)

  • 21. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
    Nazirudeen R; Sridhar S; Priyanka R; Sumathi B; Natarajan V; Subbiah E; Raghavan KS; Sangumani J
    Clin Endocrinol (Oxf); 2023 Aug; 99(2):198-205. PubMed ID: 37265016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS.
    Cianci A; Panella M; Fichera M; Falduzzi C; Bartolo M; Caruso S
    Gynecol Endocrinol; 2015 Jun; 31(6):483-6. PubMed ID: 25893270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome.
    Minozzi M; Costantino D; Guaraldi C; Unfer V
    Gynecol Endocrinol; 2011 Nov; 27(11):920-4. PubMed ID: 21417594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
    Sobbrio GA; Granata A; D'Arrigo F; Arena D; Panacea A; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1990; 21(3):139-41. PubMed ID: 2149912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
    De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
    Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-sensitizing effect and antioxidant action of alpha lipoic acid in oligomenorrheic women with polycystic ovary syndrome.
    Scarinci E; Notaristefano G; Tropea A; Fabozzi SM; Alesiani O; Meucci E; Silvestrini A; Cintoni M; Diterlizzi A; Lanzone A; Apa R
    Minerva Obstet Gynecol; 2023 Apr; 75(2):165-171. PubMed ID: 34825791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
    Laganà AS; Barbaro L; Pizzo A
    Arch Gynecol Obstet; 2015 May; 291(5):1181-6. PubMed ID: 25416201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome.
    Cupisti S; Kajaia N; Dittrich R; Duezenli H; W Beckmann M; Mueller A
    Eur J Endocrinol; 2008 May; 158(5):711-9. PubMed ID: 18426831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
    Mitkov M; Pehlivanov B; Terzieva D
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome.
    Woods KS; Reyna R; Azziz R
    Fertil Steril; 2002 Jun; 77(6):1125-7. PubMed ID: 12057716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
    Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
    Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?
    Laganà AS; Monti N; Fedeli V; Gullo G; Bizzarri M
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1241-1247. PubMed ID: 35253180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study.
    Troisi J; Cinque C; Giugliano L; Symes S; Richards S; Adair D; Cavallo P; Sarno L; Scala G; Caiazza M; Guida M
    J Ovarian Res; 2019 Mar; 12(1):25. PubMed ID: 30904021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin therapy in women with polycystic ovary syndrome.
    Aruna J; Mittal S; Kumar S; Misra R; Dadhwal V; Vimala N
    Int J Gynaecol Obstet; 2004 Dec; 87(3):237-41. PubMed ID: 15548396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective.
    Pasquali R; Zanotti L; Fanelli F; Mezzullo M; Fazzini A; Morselli Labate AM; Repaci A; Ribichini D; Gambineri A
    J Clin Endocrinol Metab; 2016 May; 101(5):2013-22. PubMed ID: 26964728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association of body mass index and biochemical hyperandrogenaemia in women with and without polycystic ovary syndrome.
    Yasmin E; Balen AH; Barth JH
    Eur J Obstet Gynecol Reprod Biol; 2013 Feb; 166(2):173-7. PubMed ID: 23102586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The link between metabolic features and TSH levels in polycystic ovary syndrome is modulated by the body weight: an euglycaemic-hyperinsulinaemic clamp study.
    Tagliaferri V; Romualdi D; Guido M; Mancini A; De Cicco S; Di Florio C; Immediata V; Di Segni C; Lanzone A
    Eur J Endocrinol; 2016 Nov; 175(5):433-41. PubMed ID: 27511825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.